Photo of Monika Davare, Ph.D.

Monika Davare Ph.D.

  • (503) 494-5056
    • Assistant Professor of Pediatrics, Division of Hematology and Oncology School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine
    • Cancer Biology Graduate Program School of Medicine

The Davare laboratory’s research goals are directed towards overcoming the therapeutic bottleneck in rare but aggressive pediatric and adult cancers. Oncogenomics-driven big data approaches effectively identify lead drug targets for cancer, but bottlenecks arise from a lack or slower pace of functionally testing, vetting and optimizing leads for therapeutic development. Using complementary in vitro and in vivo experimental model systems coupled with patient-derived genomic data, we have successfully identified driving kinase pathways and validated small-molecule inhibitor therapies for targeting distinct genomic subsets of glioblastoma, sarcoma, medulloblastoma and non-small cell lung cancer. We have active cross-institutional collaborations with clinical oncologists to facilitate transfer of our bench discoveries into clinical trials and as needed, validate clinical findings back at the bench. Dr. Davare combines her expertise in areas of regulation of kinases, kinase-driven pathways, cell surface receptors, and ion channels with her molecular pharmacology knowledge base to provide leadership to this research program.


  • B.A., University of Maine (Zoology/Philosophy) 1995
  • Ph.D., University of Wisconsin-Madison (Molecular and Cellular Pharmacology), Madison Wisconsin 2000


  • "Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes." Leukemia  In: , 29.03.2018, p. 1-14.
  • "Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line." Pediatric Blood and Cancer In: , 2017.
  • "IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma." Scientific Reports  In: , Vol. 6, 27012, 03.06.2016.
  • "A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer." Clinical Cancer Research In: , Vol. 22, No. 10, 15.05.2016, p. 2351-2358.
  • "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors." Proceedings of the National Academy of Sciences of the United States of America In: , Vol. 112, No. 39, 29.09.2015, p. E5381-E5390.
  • "Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia." Oncogene In: , Vol. 34, No. 23, 04.06.2015, p. 2991-2999.
  • "Therapeutically targetable ALK mutations in leukemia." Cancer Research In: , Vol. 75, No. 11, 01.06.2015, p. 2146-2150.
  • "Detecting and targetting oncogenic fusion proteins in the genomic era." Biology of the Cell In: , Vol. 107, No. 5, 01.05.2015, p. 111-129.
  • "Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma." Oncotarget In: , Vol. 6, No. 22, 2015, p. 18921-18932.
  • "Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells." Biochemical and Biophysical Research Communications  In: , Vol. 450, No. 1, 18.07.2014, p. 555-560.
  • "Leptin-induced spine formation requires TrpC channels and the CaM kinase cascade in the hippocampus." Journal of Neuroscience In: , Vol. 34, No. 30, 2014, p. 10022-10033.
  • "Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins." Proceedings of the National Academy of Sciences of the United States of America In: , Vol. 110, No. 48, 26.11.2013, p. 19519-19524.
  • "Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target." Proceedings of the National Academy of Sciences of the United States of America In: , Vol. 110, No. 48, 26.11.2013, p. 19513-19518.
  • "A Genome-Wide Screen of CREB Occupancy Identifies the RhoA Inhibitors Par6C and Rnd3 as Regulators of BDNF-Induced Synaptogenesis." PLoS One In: , Vol. 8, No. 6, e64658, 06.06.2013.
  • "Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model." Journal of Pediatric Hematology/Oncology  In: , Vol. 34, No. 2, 03.2012, p. 116-121.
  • "Corrigendum to "An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling" [YMCNE (2010) 146-156]." Molecular and Cellular Neuroscience In: , Vol. 49, No. 2, 02.2012, p. 250.
  • "Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma." Journal of Neuro-Oncology  In: , Vol. 105, No. 3, 12.2011, p. 475-483.
  • "Calmodulin-kinases regulate basal and estrogen stimulated medulloblastoma migration via Rac1." Journal of Neuro-Oncology In: , Vol. 104, No. 1, 08.2011, p. 65-82.
  • "Analysis of CaM-kinase signaling in cells." Cell Calcium In: , Vol. 50, No. 1, 07.2011, p. 1-8.
  • "Long-term potentiation-dependent spine enlargement requires synaptic Ca2+-permeable AMPA receptors recruited by CaM-kinase I." Journal of Neuroscience In: , Vol. 30, No. 35, 01.09.2010, p. 11565-11575.
  • "ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells." Molecular and Cellular Biochemistry In: , Vol. 335, No. 1-2, 02.2010, p. 155-171.
  • "An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling." Molecular and Cellular Neuroscience In: , Vol. 43, No. 1, 01.2010, p. 146-156.
  • "Transient receptor potential canonical 5 channels activate Ca 2+/calmodulin kinase Iγ to promote axon formation in hippocampal neurons." Journal of Neuroscience In: , Vol. 29, No. 31, 05.08.2009, p. 9794-9808.
  • "Statins decrease dendritic arborization in rat sympathetic neurons by blocking RhoA activation." Journal of Neurochemistry In: , Vol. 108, No. 4, 02.2009, p. 1057-1071.
  • "An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 105, No. 26, 01.07.2008, p. 9093-9098.
  • "Activity-Dependent Synaptogenesis : Regulation by a CaM-Kinase Kinase/CaM-Kinase I/βPIX Signaling Complex." Neuron In: , Vol. 57, No. 1, 10.01.2008, p. 94-107.
  • "Critical role of cAMP-dependent protein kinase anchoring to the L-type calcium channel Cav1.2 via A-kinase anchor protein 150 in neurons." Biochemistry In: , Vol. 46, No. 6, 13.02.2007, p. 1635-1646.
  • "Bidirectional regulation of cytoplasmic polyadenylation element-binding protein phosphorylation by Ca/calmodulin-dependent protein kinase II and protein phosphatase 1 during hippocampal long-term potentiation." Journal of Neuroscience In: , Vol. 25, No. 23, 08.06.2005, p. 5604-5610.
  • "Inhibition of calcium/calmodulin-dependent protein kinase kinase by protein 14-3-3." Journal of Biological Chemistry In: , Vol. 279, No. 50, 10.12.2004, p. 52191-52199.
  • "Mitogen- and Stress-Activated Protein Kinase 1 Mediates cAMP Response Element-Binding Protein Phosphorylation and Activation by Neurotrophins." Journal of Neuroscience  In: , Vol. 24, No. 18, 05.05.2004, p. 4324-4332.

Additional information

Edit profile